Comparison

Eloralintide vs. Retatrutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Retatrutide

Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Eloralintide	Retatrutide
Germany	Unapproved	Unapproved
JP	—	Unapproved
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Eloralintide and Retatrutide?: Eloralintide is classified as "Metabolic", while Retatrutide is classified as "Metabolic". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or Retatrutide?: The highest available evidence level is "Human RCT" for Eloralintide and "Human RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and Retatrutide in Germany and the United States?: Germany: Eloralintide — Unapproved, Retatrutide — Unapproved. United States: Eloralintide — Unapproved, Retatrutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

Retatrutide

Germany

Unapproved

—

Unapproved

United States

Unapproved

Frequently asked questions

What is the difference between Eloralintide and Retatrutide?

Eloralintide is classified as "Metabolic", while Retatrutide is classified as "Metabolic". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or Retatrutide?

The highest available evidence level is "Human RCT" for Eloralintide and "Human RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and Retatrutide in Germany and the United States?

Germany: Eloralintide — Unapproved, Retatrutide — Unapproved. United States: Eloralintide — Unapproved, Retatrutide — Unapproved. These are factual summaries with source and review date on the individual pages.